Need help finding what you are looking for?
Contact Us
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393505
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393505
NA Stroke Market - Industry Trends and Forecast to 2034
PUBLISHED:
PAGES: 230 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
North America Stroke market is projected to register a CAGR of 7.3% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation
North America Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (U.S., Canada and Mexico) - Industry trends and forecast to 2030.
Overview of North America Stroke Market Dynamics
- Drivers
- Rising incidences of stroke
- Increasing number of patients with hypertension and coronary heart diseases
- Restraints
- High cost associated with treatment of stroke
- Side-effects associated with medication
- Opportunities
- Expansion of telemedicine and remote monitoring
- Innovative therapies in pipeline for stroke treatment
Market Players
Some of the major market players operating in the North America stroke market are:
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH.
- F. Hoffmann-La Roche Ltd
- DAIICHI SANKYO COMPANY, LIMITED.
- Sanofi
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sandoz AG
- Pfizer Inc.
- Medtronic
- Abbott
- Viatris Inc.
- AstraZeneca
- Penumbra, Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fresenius Kabi USA
- Teva Pharmaceuticals USA, Inc.
- Lupin
- Amneal Pharmaceuticals LLC.
TABLE OF CONTENTS
1 INTRODUCTION 21
- 1.1 OBJECTIVES OF THE STUDY 21
- 1.2 MARKET DEFINITION 21
- 1.3 OVERVIEW OF THE NORTH AMERICA STROKE MARKET 21
- 1.4 LIMITATIONS 23
- 1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 28
- 2.1 MARKETS COVERED 28
- 2.2 GEOGRAPHICAL SCOPE 29
- 2.3 YEARS CONSIDERED FOR THE STUDY 30
- 2.4 CURRENCY AND PRICING 30
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
- 2.6 MULTIVARIATE MODELLING 34
- 2.7 TYPE LIFELINE CURVE 35
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
- 2.9 DBMR MARKET POSITION GRID 37
- 2.10 MARKET APPLICATION COVERAGE GRID 38
- 2.11 VENDOR SHARE ANALYSIS 39
- 2.12 SECONDARY SOURCES 40
- 2.13 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 44
- 4.1 PESTEL'S MODEL 45
- 4.2 PORTER'S 5 FORCES 46
5 EPIDEMIOLOGY 47
6 NORTH AMERICA STROKE MARKET, REGULATORY FRAMEWORK 48
- 6.1 REGULATION IN U.S 48
- 6.2 REGULATION IN EUROPE 49
- 6.3 REGULATION IN CHINA 50
- 6.4 REGULATION IN JAPAN 51
- 6.5 REGULATION IN SOUTH AFRICA 52
7 MARKET OVERVIEW 53
- 7.1 DRIVERS 55
- 7.1.1 RISING INCIDENCES OF STROKE 55
- 7.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 56
- 7.1.3 INCREASING DIABETIC AND OBESE POPULATION 57
- 7.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR STROKE TREATMENT 58
- 7.2 RESTRAINTS 59
- 7.2.1 HIGH COST ASSOCIATED WITH TREATMENT OF STROKE 59
- 7.2.2 SIDE-EFFECTS ASSOCIATED WITH MEDICATION 60
- 7.3 OPPORTUNITIES 61
- 7.3.1 EXPANSION OF TELEMEDICINE AND REMOTE MONITORING 61
- 7.3.2 INNOVATIVE THERAPIES IN PIPELINE FOR STROKE TREATMENT 61
- 7.4 CHALLENGES 62
- 7.4.1 INACCURATE DIAGNOSIS OF STROKES S 62
- 7.4.2 COMPLICATIONS IN MANAGING STROKE IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS 63
8 NORTH AMERICA STROKE MARKET, BY TYPE 64
- 8.1 OVERVIEW 65
- 8.2 ISCHEMIC STROKE 68
- 8.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 69
- 8.2.2 EMBOLIC (CEREBRAL EMBOLISM) 69
- 8.3 HEMORRHAGIC STROKE 70
- 8.3.1 SUBARACHNOID HEMORRHAGE 71
- 8.3.2 INTRACEREBRAL HEMORRHAGE 71
- 8.4 TRANSIENT ISCHEMIC ATTACK (TIA) 71
9 NORTH AMERICA STROKE MARKET, BY TREATMENT 72
- 9.1 OVERVIEW 73
- 9.2 MEDICATION 76
- 9.2.1 BY CLASS 77
- 9.2.1.1 BLOOD PRESSURE MEDICINES 78
- 9.2.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 79
- 9.2.1.1.1.1 RAMIPRIL 79
- 9.2.1.1.1.2 LISINOPRIL 79
- 9.2.1.1.1.3 ENALAPRIL 79
- 9.2.1.1.1.4 PERINDOPRIL 79
- 9.2.1.1.1.5 OTHER 80
- 9.2.1.1.2 DIURETICS 80
- 9.2.1.1.2.1 INDAPAMIDE 80
- 9.2.1.1.2.2 BENDROFLUMETHIAZIDE 80
- 9.2.1.1.2.3 SPIRONOLACTONE 80
- 9.2.1.1.2.4 AMILORIDE 81
- 9.2.1.1.2.5 OTHER 81
- 9.2.1.1.3 CALCIUM CHANNEL BLOCKERS 81
- 9.2.1.1.3.1 AMLODIPINE 81
- 9.2.1.1.3.2 NIFEDIPINE 81
- 9.2.1.1.3.3 VERAPAMIL 82
- 9.2.1.1.3.4 NICARDIPINE 82
- 9.2.1.1.3.5 FELODIPINE 82
- 9.2.1.1.3.6 NIMODIPINE 82
- 9.2.1.1.3.7 OTHER 82
- 9.2.1.1.4 BETA BLOCKERS 83
- 9.2.1.1.4.1 ATENOLOL 83
- 9.2.1.1.4.2 BISOPROLOL 83
- 9.2.1.1.4.3 LABETOLOL 83
- 9.2.1.1.4.4 OTHER 83
- 9.2.1.1.5 ALPHA BLOCKERS 84
- 9.2.1.1.5.1 DOXAZOSIN 84
- 9.2.1.1.5.2 OTHER 84
- 9.2.1.1.6 OTHERS 84
- 9.2.1.1 ANTIPLATELET DRUGS 85
- 9.2.1.1.1 ASPIRIN 85
- 9.2.1.1.2 CLOPIDOGREL 85
- 9.2.1.1.3 DIPYRIDAMOLE 85
- 9.2.1.1.4 TICLOPIDINE 85
- 9.2.1.1.5 OTHERS 85
- 9.2.1.2 ANTICOAGULANTS 86
- 9.2.1.2.1 WARFARIN 86
- 9.2.1.2.2 APIXABAN 86
- 9.2.1.2.3 DABIGATRAN 86
- 9.2.1.2.4 HEPARIN 86
- 9.2.1.2.5 RIVAROXABAN 87
- 9.2.1.2.6 OTHERS 87
- 9.2.1.3 TISSUE PLASMINOGEN ACTIVATOR (TPA) 87
- 9.2.1.3.1 ALTEPLASE 87
- 9.2.1.3.2 TENECTEPLASE 87
- 9.2.1.3.3 RETEPLASE 87
- 9.2.1.3.4 ANISTREPLASE 88
- 9.2.1.3.5 OTHERS 88
- 9.2.1.4 STATINS 88
- 9.2.1.4.1 ATORVASTATIN 88
- 9.2.1.4.2 SIMVASTATIN 88
- 9.2.1.4.3 LOVASTATIN 88
- 9.2.1.4.4 ROSUVASTATIN 89
- 9.2.1.4.5 FLUVASTATIN 89
- 9.2.1.4.6 PRAVASTATIN 89
- 9.2.1.4.7 PITAVASTATIN 89
- 9.2.1.4.8 OTHERS 89
- 9.2.1.5 VITAMIN K 89
- 9.2.1.6 SUPPORTIVE MEDICATION 90
- 9.2.1.6.1 NUTRITIONAL SUPPLEMENTS 90
- 9.2.1.6.2 ANTIPYRETICS 90
- 9.2.1.6.3 OTHERS 90
- 9.2.1.1 BLOOD PRESSURE MEDICINES 78
- 9.2.2 BY DRUG TYPE 91
- 9.2.2.1 GENERICS 91
- 9.2.2.2 BRANDED 92
- 9.2.2.2.1 ELIQUIS 92
- 9.2.2.2.2 PRADAXA 92
- 9.2.2.2.3 ACTIVASE 92
- 9.2.2.2.4 ASPIRIN 93
- 9.2.2.2.5 PLAVIX 93
- 9.2.2.2.6 AGGRENOX 93
- 9.2.2.2.7 OTHERS 93
- 9.2.3 BY ROUTE OF ADMINISTRATION 94
- 9.2.3.1 ORAL 94
- 9.2.3.1.1 TABLET 95
- 9.2.3.1.2 CAPSULES 95
- 9.2.3.1.3 Others 95
- 9.2.3.2 PARENTERAL 96
- 9.2.3.2.1 INTRAVENOUS 96
- 9.2.3.2.2 SUBCUTANEOUS 96
- 9.2.3.3 OTHERS 96
- 9.2.3.1 ORAL 94
- 9.2.4 BY MODE OF PURCHASE 97
- 9.2.4.1 PRESCRIPTION 97
- 9.2.4.2 OVER THE COUNTER (OTC) 97
- 9.2.5 BY THERPAY TYPE 98
- 9.2.5.1 COMBINATION THERAPY 98
- 9.2.5.2 MONOTHERAPY 98
- 9.2.1 BY CLASS 77
- 9.3 SURGERY 99
- 9.3.1 EMBOLIC COILS 100
- 9.3.2 ASPIRATION CATHETERS 100
- 9.3.3 STENT RETRIEVER 100
- 9.3.4 SURGICAL CLIPPING 100
- 9.3.5 OTHERS 100
- 9.4 OTHER THERAPY 101
- 9.4.1 PHYSICAL THERAPY 101
- 9.4.2 OCCUPATIONAL THERAPY 101
- 9.4.3 SPEECH THERAPY 102
- 9.4.4 OTHERS 102
10 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS 103
- 10.1 OVERVIEW 104
- 10.2 IMAGING TEST 107
- 10.2.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 107
- 10.2.2 MAGNETIC RESONANCE IMAGING (MRI) 108
- 10.2.3 CAROTID ULTRASOUND 108
- 10.2.4 CEREBRAL ANGIOGRAM 108
- 10.3 BLOOD TEST 109
- 10.4 ECHOCARDIOGRAM 109
- 10.5 LUMBAR PUNCTURE 110
- 10.6 OTHERS 110
11 NORTH AMERICA STROKE MARKET, BY GENDER 111
- 11.1 OVERVIEW 112
- 11.2 FEMALE 115
- 11.3 MALE 116
12 NORTH AMERICA STROKE MARKET, BY END USER 117
- 12.1 OVERVIEW 118
- 12.2 HOSPITALS & CLINICS 121
- 12.3 SPECIALTY CLINICS 122
- 12.4 AMBULATORY SURGICAL CENTER 122
- 12.5 HOMECARE 123
- 12.6 LABORATORIES 123
- 12.7 OTHERS 124
13 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL 125
- 13.1 OVERVIEW 126
- 13.2 DIRECT 129
- 13.3 RETAIL 129
- 13.4 ONLINE 130
14 NORTH AMERICA STROKE MARKET, BY REGION 131
- 14.1 NORTH AMERICA 133
- 14.1.1 U.S. 145
- 14.1.2 CANADA 156
- 14.1.3 MEXICO 167
15 NORTH AMERICA STROKE MARKET, COMPANY LANDSCAPE 178
- 15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 178
16 SWOT ANALYSIS 179
17 COMPANY PROFILES 180
- 17.1 BRISTOL-MYERS SQUIBB COMPANY 180
- 17.1.1 COMPANY SNAPSHOT 180
- 17.1.2 REVENUE ANALYSIS 180
- 17.1.3 COMPANY SHARE ANALYSIS 181
- 17.1.4 PRODUCT PORTFOLIO 181
- 17.1.5 RECENT DEVELOPMENT 182
- 17.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 183
- 17.2.1 COMPANY SNAPSHOT 183
- 17.2.2 PRODUCT PORTFOLIO 183
- 17.2.3 COMPANY SHARE ANALYSIS 184
- 17.2.4 RECENT DEVELOPMENT 184
- 17.3 F. HOFFMANN-LA ROCHE LTD 185
- 17.3.1 COMPANY SNAPSHOT 185
- 17.3.2 REVENUE ANALYSIS 185
- 17.3.3 COMPANY SHARE ANALYSIS 186
- 17.3.4 PRODUCT PORTFOLIO 186
- 17.3.5 RECENT DEVELOPMENT 186
- 17.4 DAIICHI SANKYO COMPANY, LIMITED 187
- 17.4.1 COMPANY SNAPSHOT 187
- 17.4.2 REVENUE ANALYSIS 187
- 17.4.3 COMPANY SHARE ANALYSIS 188
- 17.4.4 PRODUCT PORTFOLIO 188
- 17.4.5 RECENT DEVELOPMENT 189
- 17.5 SANOFI 190
- 17.5.1 COMPANY SNAPSHOT 190
- 17.5.2 REVENUE ANALYSIS 190
- 17.5.3 COMPANY SHARE ANALYSIS 191
- 17.5.4 PRODUCT PORTFOLIO 191
- 17.5.5 RECENT DEVELOPMENT 191
- 17.6 ABBOTT 193
- 17.6.1 COMPANY SNAPSHOT 193
- 17.6.2 REVENUE ANALYSIS 193
- 17.6.3 PRODUCT PORTFOLIO 194
- 17.6.4 RECENT DEVELOPMENT 195
- 17.7 AMNEAL PHARMACEUTICALS LLC 196
- 17.7.1 COMPANY SNAPSHOT 196
- 17.7.2 REVENUE ANALYSIS 196
- 17.7.3 PRODUCT PORTFOLIO 197
- 17.7.4 RECENT DEVELOPMENT 197
- 17.8 ASTRAZENECA 198
- 17.8.1 COMPANY SNAPSHOT 198
- 17.8.2 REVENUE ANALYSIS 199
- 17.8.3 PRODUCT PORTFOLIO 199
- 17.8.4 RECENT DEVELOPMENT 199
- 17.9 BAYER AG 200
- 17.9.1 COMPANY SNAPSHOT 200
- 17.9.2 REVENUE ANALYSIS 201
- 17.9.3 PRODUCT PORTFOLIO 201
- 17.9.4 RECENT DEVELOPMENT 202
- 17.10 FRESENIUS SE & CO. KGAA 203
- 17.10.1 COMPANY SNAPSHOT 203
- 17.10.2 REVENUE ANALYSIS 203
- 17.10.3 PRODUCT PORTFOLIO 204
- 17.10.4 RECENT DEVELOPMENT 204
- 17.11 GLENMARK PHARMACEUTICALS LTD. 205
- 17.11.1 COMPANY SNAPSHOT 205
- 17.11.2 REVENUE ANALYSIS 206
- 17.11.3 PRODUCT PORTFOLIO 206
- 17.11.4 RECENT DEVELOPMENT 206
- 17.12 JOHNSON & JOHNSON SERVICES, INC. 208
- 17.12.1 COMPANY SNAPSHOT 208
- 17.12.2 REVENUE ANALYSIS 208
- 17.12.3 PRODUCT PORTFOLIO 209
- 17.12.4 RECENT DEVELOPMENT 209
- 17.13 LUPIN 210
- 17.13.1 COMPANY SNAPSHOT 210
- 17.13.2 REVENUE ANALYSIS 210
- 17.13.3 PRODUCT PORTFOLIO 211
- 17.13.4 RECENT DEVELOPMENT 212
- 17.14 MEDTRONIC 213
- 17.14.1 COMPANY SNAPSHOT 213
- 17.14.2 REVENUE ANALYSIS 213
- 17.14.3 PRODUCT PORTFOLIO 214
- 17.14.4 RECENT DEVELOPMENT 214
- 17.15 OXFORD LABORATORIES PVT. LTD. 215
- 17.15.1 COMPANY SNAPSHOT 215
- 17.15.2 PRODUCT PORTFOLIO 215
- 17.15.3 RECENT DEVELOPMENT 215
- 17.16 PENUMBRA, INC. 216
- 17.16.1 COMPANY SNAPSHOT 216
- 17.16.2 REVENUE ANALYSIS 216
- 17.16.3 PRODUCT PORTFOLIO 217
- 17.16.4 RECENT DEVELOPMENT 217
- 17.17 PFIZER INC. 218
- 17.17.1 COMPANY SNAPSHOT 218
- 17.17.2 REVENUE ANALYSIS 218
- 17.17.3 PRODUCT PORTFOLIO 219
- 17.17.4 RECENT DEVELOPMENT 219
- 17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 220
- 17.18.1 COMPANY SNAPSHOT 220
- 17.18.2 REVENUE ANALYSIS 220
- 17.18.3 PRODUCT PORTFOLIO 221
- 17.18.4 RECENT DEVELOPMENT 221
- 17.19 TEVA PHARMACEUTICALS USA, INC. 222
- 17.19.1 COMPANY SNAPSHOT 222
- 17.19.2 REVENUE ANALYSIS 222
- 17.19.3 PRODUCT PORTFOLIO 223
- 17.19.4 RECENT DEVELOPMENT 223
- 17.20 VIATRIS INC. 224
- 17.20.1 COMPANY SNAPSHOT 224
- 17.20.2 REVENUE ANALYSIS 224
- 17.20.3 PRODUCT PORTFOLIO 225
- 17.20.4 RECENT DEVELOPMENT 225
18 QUESTIONNAIRE 226
19 RELATED REPORTS 230
- 17.11.4 RECENT DEVELOPMENT 206
- 17.12 JOHNSON & JOHNSON SERVICES, INC. 208
- 17.12.1 COMPANY SNAPSHOT 208
- 17.12.2 REVENUE ANALYSIS 208
- 17.12.3 PRODUCT PORTFOLIO 209
- 17.12.4 RECENT DEVELOPMENT 209
- 17.13 LUPIN 210
- 17.13.1 COMPANY SNAPSHOT 210
- 17.13.2 REVENUE ANALYSIS 210
- 17.13.3 PRODUCT PORTFOLIO 211
- 17.13.4 RECENT DEVELOPMENT 212
- 17.14 MEDTRONIC 213
- 17.14.1 COMPANY SNAPSHOT 213
- 17.14.2 REVENUE ANALYSIS 213
- 17.14.3 PRODUCT PORTFOLIO 214
- 17.14.4 RECENT DEVELOPMENT 214
- 17.15 OXFORD LABORATORIES PVT. LTD. 215
- 17.15.1 COMPANY SNAPSHOT 215
- 17.15.2 PRODUCT PORTFOLIO 215
- 17.15.3 RECENT DEVELOPMENT 215
- 17.16 PENUMBRA, INC. 216
- 17.16.1 COMPANY SNAPSHOT 216
- 17.16.2 REVENUE ANALYSIS 216
- 17.16.3 PRODUCT PORTFOLIO 217
- 17.16.4 RECENT DEVELOPMENT 217
- 17.17 PFIZER INC. 218
- 17.17.1 COMPANY SNAPSHOT 218
- 17.17.2 REVENUE ANALYSIS 218
- 17.17.3 PRODUCT PORTFOLIO 219
- 17.17.4 RECENT DEVELOPMENT 219
- 17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 220
- 17.18.1 COMPANY SNAPSHOT 220
- 17.18.2 REVENUE ANALYSIS 220
- 17.18.3 PRODUCT PORTFOLIO 221
- 17.18.4 RECENT DEVELOPMENT 221
- 17.19 TEVA PHARMACEUTICALS USA, INC. 222
- 17.19.1 COMPANY SNAPSHOT 222
- 17.19.2 REVENUE ANALYSIS 222
- 17.19.3 PRODUCT PORTFOLIO 223
- 17.19.4 RECENT DEVELOPMENT 223
- 17.20 VIATRIS INC. 224
- 17.20.1 COMPANY SNAPSHOT 224
- 17.20.2 REVENUE ANALYSIS 224
- 17.20.3 PRODUCT PORTFOLIO 225
- 17.20.4 RECENT DEVELOPMENT 225
18 QUESTIONNAIRE 226
19 RELATED REPORTS 230
LIST OF TABLES
- TABLE 1 NORTH AMERICA STROKE MARKET, BY TYPE, 2022-2030 (USD THOUSAND) 67
- TABLE 2 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
- TABLE 3 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 69
- TABLE 4 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
- TABLE 5 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 70
- TABLE 6 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK (TIA) IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
- TABLE 7 NORTH AMERICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 75
- TABLE 8 NORTH AMERICA MEDICATION IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
- TABLE 9 NORTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 77
- TABLE 10 NORTH AMERICA BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 78
- TABLE 11 NORTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 79
- TABLE 12 NORTH AMERICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 80
- TABLE 13 NORTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 81
- TABLE 14 NORTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 83
- TABLE 15 NORTH AMERICA ALPHA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 84
- TABLE 16 NORTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 85
- TABLE 17 NORTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 86
- TABLE 18 NORTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 87
- TABLE 19 NORTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 88
- TABLE 20 NORTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 90
- TABLE 21 NORTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 91
- TABLE 22 NORTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 92
- TABLE 23 NORTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 94
- TABLE 24 NORTH AMERICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 94
- TABLE 25 NORTH AMERICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 96
- TABLE 26 NORTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 97
- TABLE 27 NORTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND) 98
- TABLE 28 NORTH AMERICA SURGERY IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
- TABLE 29 NORTH AMERICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 99
- TABLE 30 NORTH AMERICA OTHER THERAPY IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
- TABLE 31 NORTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 101
- TABLE 32 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND) 106
- TABLE 33 NORTH AMERICA IMAGING TEST IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
- TABLE 34 NORTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
- TABLE 35 NORTH AMERICA BLOOD TEST IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 109
- TABLE 36 NORTH AMERICA ECHOCARDIOGRAM IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 109
- TABLE 37 NORTH AMERICA LUMBAR PUNCTURE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
- TABLE 38 NORTH AMERICA OTHERS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
- TABLE 39 NORTH AMERICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 114
- TABLE 40 NORTH AMERICA FEMALE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 115
- TABLE 41 NORTH AMERICA MALE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 116
- TABLE 42 NORTH AMERICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
- TABLE 43 NORTH AMERICA HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 121
- TABLE 44 NORTH AMERICA SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 122
- TABLE 45 NORTH AMERICA AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 122
- TABLE 46 NORTH AMERICA HOMECARE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
- TABLE 47 NORTH AMERICA LABORATORIES IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
- TABLE 48 NORTH AMERICA OTHERS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 124
- TABLE 49 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
- TABLE 50 NORTH AMERICA DIRECT IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 129
- TABLE 51 NORTH AMERICA RETAIL IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 129
- TABLE 52 NORTH AMERICA ONLINE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND) 130
- TABLE 53 NORTH AMERICA STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 133
- TABLE 54 NORTH AMERICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
- TABLE 55 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
- TABLE 56 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
- TABLE 57 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 134
- TABLE 58 NORTH AMERICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 134
- TABLE 59 NORTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 135
- TABLE 60 NORTH AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 135
- TABLE 61 NORTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 136
- TABLE 62 NORTH AMERICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 136
- TABLE 63 NORTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 137
- TABLE 64 NORTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 137
- TABLE 65 NORTH AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 137
- TABLE 66 NORTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 138
- TABLE 67 NORTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 138
- TABLE 68 NORTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 139
- TABLE 69 NORTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 139
- TABLE 70 NORTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 140
- TABLE 71 NORTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 140
- TABLE 72 NORTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 140
- TABLE 73 NORTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
- TABLE 74 NORTH AMERICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
- TABLE 75 NORTH AMERICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
- TABLE 76 NORTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 141
- TABLE 77 NORTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND) 142
- TABLE 78 NORTH AMERICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 142
- TABLE 79 NORTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 142
- TABLE 80 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND) 143
- TABLE 81 NORTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
- TABLE 82 NORTH AMERICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 143
- TABLE 83 NORTH AMERICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
- TABLE 84 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
- TABLE 85 U.S. STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
- TABLE 86 U.S. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
- TABLE 87 U.S. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
- TABLE 88 U.S. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 145
- TABLE 89 U.S. STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 146
- TABLE 90 U.S. MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 146
- TABLE 91 U.S. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 147
- TABLE 92 U.S. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 147
- TABLE 93 U.S. DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 148
- TABLE 94 U.S. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 148
- TABLE 95 U.S. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 149
- TABLE 96 U.S. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 149
- TABLE 97 U.S. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 149
- TABLE 98 U.S. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 150
- TABLE 99 U.S. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 150
- TABLE 100 U.S. STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 151
- TABLE 101 U.S. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 151
- TABLE 102 U.S. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 151
- TABLE 103 U.S. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 152
- TABLE 104 U.S. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
- TABLE 105 U.S. ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
- TABLE 106 U.S. PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 153
- TABLE 107 U.S. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 153
- TABLE 108 U.S. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND) 153
- TABLE 109 U.S. SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 153
- TABLE 110 U.S. OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 154
- TABLE 111 U.S. STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND) 154
- TABLE 112 U.S. IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
- TABLE 113 U.S. STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 155
- TABLE 114 U.S. STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
- TABLE 115 U.S. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
- TABLE 116 CANADA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
- TABLE 117 CANADA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
- TABLE 118 CANADA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
- TABLE 119 CANADA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 156
- TABLE 120 CANADA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 157
- TABLE 121 CANADA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 157
- TABLE 122 CANADA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 158
- TABLE 123 CANADA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 158
- TABLE 124 CANADA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 159
- TABLE 125 CANADA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 159
- TABLE 126 CANADA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 160
- TABLE 127 CANADA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 160
- TABLE 128 CANADA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 160
- TABLE 129 CANADA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 161
- TABLE 130 CANADA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 161
- TABLE 131 CANADA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 162
- TABLE 132 CANADA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 162
- TABLE 133 CANADA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 162
- TABLE 134 CANADA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 163
- TABLE 135 CANADA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 163
- TABLE 136 CANADA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 163
- TABLE 137 CANADA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 164
- TABLE 138 CANADA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 164
- TABLE 139 CANADA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND) 164
- TABLE 140 CANADA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 164
- TABLE 141 CANADA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 165
- TABLE 142 CANADA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND) 165
- TABLE 143 CANADA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 165
- TABLE 144 CANADA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 166
- TABLE 145 CANADA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND) 166
- TABLE 146 CANADA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 166
- TABLE 147 MEXICO STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
- TABLE 148 MEXICO ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
- TABLE 149 MEXICO HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
- TABLE 150 MEXICO STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 167
- TABLE 151 MEXICO STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 168
- TABLE 152 MEXICO MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 168
- TABLE 153 MEXICO BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 169
- TABLE 154 MEXICO ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 169
- TABLE 155 MEXICO DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 170
- TABLE 156 MEXICO CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 170
- TABLE 157 MEXICO BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 171
- TABLE 158 MEXICO ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 171
- TABLE 159 MEXICO ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 171
- TABLE 160 MEXICO ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 172
- TABLE 161 MEXICO TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 172
- TABLE 162 MEXICO STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 173
- TABLE 163 MEXICO SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND) 173
- TABLE 164 MEXICO MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 173
- TABLE 165 MEXICO BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 174
- TABLE 166 MEXICO MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 174
- TABLE 167 MEXICO ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 174
- TABLE 168 MEXICO PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 175
- TABLE 169 MEXICO MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 175
- TABLE 170 MEXICO MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND) 175
- TABLE 171 MEXICO SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 175
- TABLE 172 MEXICO OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 176
- TABLE 173 MEXICO STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND) 176
- TABLE 174 MEXICO IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 176
- TABLE 175 MEXICO STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 177
- TABLE 176 MEXICO STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND) 177
- TABLE 177 MEXICO STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 177
LIST OF FIGURES
- FIGURE 1 NORTH AMERICA STROKE MARKET: SEGMENTATION 28
- FIGURE 2 NORTH AMERICA STROKE MARKET: DATA TRIANGULATION 31
- FIGURE 3 NORTH AMERICA STROKE MARKET: DROC ANALYSIS 32
- FIGURE 4 NORTH AMERICA STROKE MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS 33
- FIGURE 5 NORTH AMERICA STROKE MARKET: COMPANY RESEARCH ANALYSIS 33
- FIGURE 6 NORTH AMERICA STROKE MARKET: INTERVIEW DEMOGRAPHICS 36
- FIGURE 7 NORTH AMERICA STROKE MARKET: DBMR MARKET POSITION GRID 37
- FIGURE 8 NORTH AMERICA STROKE MARKET: MARKET APPLICATION COVERAGE GRID 38
- FIGURE 9 NORTH AMERICA STROKE MARKET: VENDOR SHARE ANALYSIS 39
- FIGURE 10 NORTH AMERICA STROKE MARKET: SEGMENTATION 43
- FIGURE 11 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE IS EXPECTED TO DRIVE THE NORTH AMERICA STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 44
- FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA STROKE MARKET IN THE FORECAST PERIOD OF 2023 & 2030 44
- FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA STROKE MARKET 54
- FIGURE 14 NORTH AMERICA STROKE MARKET: BY TYPE, 2022 65
- FIGURE 15 NORTH AMERICA STROKE MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 66
- FIGURE 16 NORTH AMERICA STROKE MARKET: BY TYPE, CAGR (2023-2030) 66
- FIGURE 17 NORTH AMERICA STROKE MARKET: BY TYPE, LIFELINE CURVE 67
- FIGURE 18 NORTH AMERICA STROKE MARKET: BY TREATMENT, 2022 73
- FIGURE 19 NORTH AMERICA STROKE MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 74
- FIGURE 20 NORTH AMERICA STROKE MARKET: BY TREATMENT, CAGR (2023-2030) 74
- FIGURE 21 NORTH AMERICA STROKE MARKET: BY TREATMENT, LIFELINE CURVE 75
- FIGURE 22 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS, 2022 104
- FIGURE 23 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS, 2023-2030 (USD THOUSAND) 105
- FIGURE 24 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS, CAGR (2023-2030) 105
- FIGURE 25 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS, LIFELINE CURVE 106
- FIGURE 26 NORTH AMERICA STROKE MARKET: BY GENDER, 2022 112
- FIGURE 27 NORTH AMERICA STROKE MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 113
- FIGURE 28 NORTH AMERICA STROKE MARKET: BY GENDER, CAGR (2023-2030) 113
- FIGURE 29 NORTH AMERICA STROKE MARKET: BY GENDER, LIFELINE CURVE 114
- FIGURE 30 NORTH AMERICA STROKE MARKET: BY END USER, 2022 118
- FIGURE 31 NORTH AMERICA STROKE MARKET: BY END USER, 2023-2030 (USD THOUSAND) 119
- FIGURE 32 NORTH AMERICA STROKE MARKET: BY END USER, CAGR (2023-2030) 119
- FIGURE 33 NORTH AMERICA STROKE MARKET: BY END USER, LIFELINE CURVE 120
- FIGURE 34 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2022 126
- FIGURE 35 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 127
- FIGURE 36 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 127
- FIGURE 37 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
- FIGURE 38 NORTH AMERICA STROKE MARKET: SNAPSHOT (2022) 132
- FIGURE 39 NORTH AMERICA STROKE MARKET: COMPANY SHARE 2022 (%) 178
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.